EP2714894B1 - Bioartifizielle proximale tubulussysteme und anwendungsverfahren - Google Patents

Bioartifizielle proximale tubulussysteme und anwendungsverfahren Download PDF

Info

Publication number
EP2714894B1
EP2714894B1 EP12726536.1A EP12726536A EP2714894B1 EP 2714894 B1 EP2714894 B1 EP 2714894B1 EP 12726536 A EP12726536 A EP 12726536A EP 2714894 B1 EP2714894 B1 EP 2714894B1
Authority
EP
European Patent Office
Prior art keywords
cells
kidney
derived
renal
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12726536.1A
Other languages
English (en)
French (fr)
Other versions
EP2714894A1 (de
Inventor
Christian Kazanecki
David C. Colter
Johanna SCHANZ
Anke HOPPENSACK
Jan Hansmann
Heike Walles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy Synthes Products Inc
Original Assignee
DePuy Synthes Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DePuy Synthes Products Inc filed Critical DePuy Synthes Products Inc
Priority to PL12726536T priority Critical patent/PL2714894T3/pl
Publication of EP2714894A1 publication Critical patent/EP2714894A1/de
Application granted granted Critical
Publication of EP2714894B1 publication Critical patent/EP2714894B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • C12N2533/92—Amnion; Decellularised dermis or mucosa

Definitions

  • the invention generally relates to a bioartificial proximal tubule device comprising a biological scaffold and one or more progenitor cells (such as a e.g. mammalian kidney-derived cells) that are differentiated into a renal proximal tubule cell monolayer on the scaffold.
  • the invention further relates to the methods of preparing and culturing the device in a bioreactor. Also provided are methods of use of the device for in vitro nephrotoxicity or pharmaceutical compound screening.
  • CKD Chronic kidney disease
  • ESRD end-stage renal disease
  • glucose reabsorption or albumin uptake cannot be assessed since there is no reliable way to introduce labeled test substances into the lumen or take samples of the luminal fluid of the tubules for assay.
  • the effects of changes in flow and physiological dynamic conditions that may occur under various in vivo scenarios cannot be assessed.
  • This application encompasses bioartificial proximal tubule devices having a decellularized biological matrix scaffold on which a monolayer of renal proximal tubule cells is formed from precursor cells (such as e.g. mammalian ( e.g. human) kidney-derived cells).
  • precursor cells such as e.g. mammalian ( e.g. human) kidney-derived cells.
  • the present invention describes a bioartificial proximal tubule device, constructed by preparing a decellularized biological matrix, seeding the biological matrix with mammalian kidney-derived cells and optionally mammalian endothelial cells. The device may then be cultured statically or matured using bioreactor culture to allow differentiation of the kidney cells into functioning proximal tubule cells. The resulting device is capable of carrying out proximal tubule functions, for example, the transport of molecules from either side of the biological membrane to the other.
  • the present invention also describes various methods of making and maturing the bioartificial proximal tubule devices.
  • the present invention also describes methods of use of the bioartificial proximal tubule devices for in vitro studies of tubule cell transport, toxicity effects of various compounds or pharmaceutical compound screening.
  • the bioartificial proximal tubule device comprises a decellularized biological matrix scaffold seeded with a one or more cells differentiable into renal cells (e.g. a precursor cell that can differentiate into renal cells) under conditions sufficient to allow the differentiation of these cells into renal proximal tubule cells whereby the differentiated cells form an epithelial monolayer on the scaffold.
  • the bioartificial proximal tubule device may optionally further comprise vascular endothelial cells.
  • the bioartificial proximal tubule device comprises a decellularized biological scaffold having at least two surfaces wherein at least one surface is seeded with one or more cells differentiable into renal cells (e.g. a precursor cell that can differentiate into a renal cell) under conditions sufficient to allow differentiation of the cells into renal proximal tubule epithelial cells, whereby the cells form a cell monolayer on the surface of the scaffold.
  • renal cells e.g. a precursor cell that can differentiate into a renal cell
  • the bioartificial proximal device comprises an decellularized biological scaffold derived from mammalian tissue having one or more surfaces and a renal proximal tubule epithelial monolayer on a surface of the scaffold, wherein the epithelial monolayer is formed by seeding the surface with one or more mammalian kidney-derived cells under conditions sufficient to allow differentiation of the kidney-derived cells into renal proximal tubule cells and formation of the monolayer.
  • the seeding of the surface may be carried out in a bioreactor.
  • a bioreactor may have an upper body element, a lower body element with an area for cell growth, and one or more connectors.
  • the one or more cells differentiable into renal cells may be primary renal tubule epithelial cells, inducible pluripotent stem cells or progenitor cells differentiated into renal cells or renal progenitor cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney, and mixtures thereof.
  • the one or more cells differentiable into renal cells are kidney-derived cells from a mammal such as e.g. a human. These kidney-derived cells may be obtained from the kidney cortex, kidney medulla, kidney subcapsular region and mixtures thereof.
  • the bioartificial proximal tubule device comprises a decellularized biological scaffold having at least two surfaces wherein at least one surface is seeded with one or more mammalian kidney-derived cells under conditions sufficient to allow differentiation of the kidney-derived cells into renal proximal tubule cells, wherein the cells form an epithelial monolayer on the surface of the scaffold.
  • the mammal may be a human and the cells may be obtained from the kidney cortex, kidney medulla or kidney subcapsular region.
  • the decellularized biological matrix scaffold is derived from mammalian tissue.
  • the scaffold is derived from mammalian tissue such as e.g. porcine tissue.
  • the scaffold may be derived from the stomach, duodenum, jejunum, ileum or colon of a mammal.
  • the scaffold is derived from small intestine submucosa.
  • the decellularized biological matrix may be derived from mucosal or submucosal tissue.
  • the kidney-derived cells are capable of self-renewal and expansion in culture, positive for the expression of one or more of Oct-4, Pax-2 and Rex-1 and negative for the expression of one or more of Sox2, FGF4, hTert and Wnt-4.
  • the kidney-derived cells are capable of self-renewal and expansion in culture, positive for the expression of one or more of Oct-4 and Pax-2 and negative for the expression of one or more of Sox2, FGF4, hTert and Wnt-4.
  • kidney-derived cells are capable of self-renewal and expansion in culture, positive for expression of at least one of Eyal, Pax-2, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR or Rex-1, and negative for expression of at least one of Sox2, FGF4, hTert or Wnt-4.
  • the kidney-derived cells may also be positive for at least one of cell-surface markers HLA I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166, or SSEA-4, and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, or E-cadherin.
  • a second surface of the scaffold may be seeded with mammalian vascular endothelial cells.
  • the vascular endothelial cells may be endothelial cells lines, endothelial progenitor cells, primary endothelial cells, microvascular endothelial cells and mixtures thereof.
  • An alternate embodiment of the invention is a bioartificial proximal tubule device comprising a decellularized biological matrix scaffold seeded with one or more precursor cells (i.e. precursor cells which can differentiate into renal cells) under conditions sufficient to allow the differentiation of the precursor cell into renal proximal tubule epithelial cells, wherein the differentiated cells form an epithelial monolayer on the scaffold.
  • the decellularized biological matrix scaffold may be derived from mammalian tissue (e.g. porcine tissue) such as e.g. mucosal or submucosal tissue.
  • decellularized biological matrix scaffold is derived from a mammalian alimentary canal.
  • the decellularized biological matrix scaffold is derived ( e.g .
  • the one or more precursor cells is selected from the group consisting of primary renal tubule epithelial cells, inducible pluripotent stem cells differentiated into renal cells or renal progenitor cells, progenitor cells differentiated into renal cells or renal progenitor cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney, and mixtures thereof.
  • the progenitor cells are human kidney-derived cells.
  • the human kidney-derived cells are capable of self-renewal and expansion in culture and are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eya1, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2, E-cadherin or GATA-4.
  • these cells are also positive for at least one of cell-surface markers HLA-I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166, or SSEA-4; and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, and CD141.
  • the cells optionally further secrete at least one of trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF; and do not secrete at least one of trophic factors PDGF-bb or IL12p70.
  • a bioartificial proximal tubule device comprising a decellularized biological scaffold having at least two surfaces wherein at least one surface is seeded with one or more precursor cells (i.e. precursor cells which can differentiate into renal cells) under conditions sufficient to allow differentiation of the cells into renal proximal tubule epithelial cells, wherein the cells form an epithelial monolayer on the surface of the scaffold.
  • the decellularized biological matrix scaffold is derived from mammalian tissue (e.g . porcine tissue).
  • the decellularized biological matrix scaffold is derived from mucosal or submucosal tissue.
  • the decellularized biological matrix scaffold is derived from a mammalian alimentary canal.
  • the decellularized biological matrix scaffold is derived ( e.g . obtained) from the stomach, duodenum, jejunum, ileum or colon of a mammal.
  • the one or more precursor cells is selected from the group consisting of primary renal tubule epithelial cells, inducible pluripotent stem cells differentiated into renal cells or renal progenitor cells, progenitor cells differentiated into renal cells or renal progenitor cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney, and mixtures thereof.
  • the progenitor cells are human kidney-derived cells.
  • the human kidney-derived cells are capable of self-renewal and expansion in culture and are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2, E-cadherin or GATA-4.
  • these cells are also positive for at least one of cell-surface markers HLA-I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166, or SSEA-4; and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, and CD141.
  • the cells optionally further secrete at least one of trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF; and do not secrete at least one of trophic factors PDGF-bb or IL12p70.
  • the second surface of the scaffold is seeded with mammalian vascular endothelial cells.
  • vascular endothelial cells may be selected from endothelial cells lines, endothelial progenitor cells, primary endothelial cells or microvascular endothelial cells.
  • one embodiment is a method of differentiating one or more precursor cells into renal cells comprising seeding a decellularized biological matrix scaffold (i . e. precursor cells which can differentiate into renal cells) with one or more precursor cells and culturing the cells on the scaffold under conditions sufficient to allow the differentiation of the precursor cell into renal proximal tubule epithelial cells, wherein the differentiated cells form an epithelial monolayer on the scaffold.
  • the decellularized biological matrix scaffold may have two surfaces.
  • the decellularized biological matrix scaffold is derived from mammalian (e.g . porcine) tissue.
  • the decellularized biological matrix scaffold may be derived ( e.g . obtained) from mucosal or submucosal tissue.
  • the decellularized biological matrix scaffold is derived from the stomach, duodenum, jejunum, ileum or colon of a mammal.
  • the methods may utilize the one or more precursor cells selected from the group consisting of primary renal tubule epithelial cells, inducible pluripotent stem cells differentiated into renal cells or renal progenitor cells, progenitor cells differentiated into renal cells or renal progenitor cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney, and mixtures thereof.
  • the progenitor cells utilized in the methods are human kidney-derived cells.
  • the human kidney-derived cells used in the methods are capable of self-renewal and expansion in culture and are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2, E-cadherin or GATA-4.
  • these cells are also positive for at least one of cell-surface markers HLA-I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166, or SSEA-4; and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, and CD141.
  • the cells secrete at least one of trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF; and do not secrete at least one of trophic factors PDGF-bb or IL12p70.
  • Another embodiment of the invention is a method of differentiating one or more cells differentiable into renal cells into renal proximal tubule epithelial cells under conditions sufficient to allow the differentiation, whereby the differentiated cells form an epithelial monolayer and whereby tension is applied to the cells.
  • the method may further comprise the step of seeding the cells on a decellularized scaffold prior to differentiating the cells.
  • the method can be used to produce a bioartificial device of the invention.
  • the decellularized biological matrix scaffold may be derived from mammalian (such as e.g. porcine) tissue such as mucosal or submucosal tissue.
  • the decellularized biological matrix scaffold is derived from a mammalian alimentary canal.
  • the decellularized biological matrix scaffold is derived from the stomach, duodenum, jejunum, ileum or colon of a mammal.
  • the one or more cells differentiable into renal cells is selected from the group consisting of primary renal tubule epithelial cells, inducible pluripotent stem cells or progenitor cells differentiated into renal cells or renal progenitor cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney and mixtures thereof.
  • the one or more cells differentiable into renal cells are mammalian kidney-derived cells (such as e.g . human kidney-derived cells).
  • the mammalian kidney-derived cells may be obtained from the kidney cortex, kidney medulla, kidney subcapsular region and mixtures thereof.
  • the kidney-derived cells are capable of self-renewal and expansion in culture, positive for the expression of one or more of Oct-4, Pax-2, and Rex-1 and negative for the expression of one or more of Sox2, FGF4, hTert and Wnt-4.
  • the kidney-derived cells are capable of self-renewal and expansion in culture, positive for expression of at least one of Eyal, Pax2, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR or Rex-1, and negative for expression of at least one of Sox2, FGF4, hTert or Wnt-4.
  • the kidney-derived cells are also positive for at least one of cell-surface markers HLA I, CD24, CD29, CD44, CD49c, CD73, CD166, or SSEA-4, and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, or E-cadherin.
  • This invention is based on the discovery that precursor cells that can differentiate into renal cells (cells differentiable into renal cells) (such e.g . kidney-derived cells), when seeded on a decellularized biological matrix scaffold under conditions that allow differentiation, form a renal proximal tubule epithelial monolayer on the surface of the scaffold.
  • precursor cells that can differentiate into renal cells such e.g . kidney-derived cells
  • a decellularized biological matrix scaffold under conditions that allow differentiation
  • “Differentiation” is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell, such as a kidney cell, for example.
  • a “differentiated or differentiation-induced cell” is one that has taken on a more specialized ("committed") position within the lineage of a cell.
  • the term “committed,” when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.
  • De-differentiation refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage of a cell.
  • the "lineage” of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to.
  • the lineage of a cell places the cell within a hereditary scheme of development and differentiation.
  • a "lineage-specific marker” refers to a characteristic specifically associated with the phenotype of cells of a lineage of interest and can be used to assess the differentiation of an uncommitted cell to the lineage of interest.
  • a “progenitor cell” is a cell that has the capacity to create progeny that are more differentiated than itself and yet retains the capacity to replenish the pool of progenitors.
  • stem cells themselves are also progenitor cells, as are the more immediate precursors to terminally differentiated cells.
  • a differentiated cell can be derived from a multipotent cell which itself is derived from a multipotent cell, and so on. While each of these multipotent cells can be considered stem cells, the range of cell types each can give rise to may vary considerably. Some differentiated cells also have the capacity to give rise to cells of greater developmental potential. Such capacity can be natural or can be induced artificially upon treatment with various factors. "Proliferation" indicates an increase in cell number.
  • Kiddney progenitor cells as used herein are mammalian (e.g . human) kidney-derived cells that can give rise to cells, such as adipocytes, or osteoblasts or can give rise to one or more types of tissue, for example, renal tissue, in addition to producing daughter cells of equivalent potential.
  • a "kidney or renal progenitor cell” is a multipotent or pluripotent cell that originates substantially from adult or fetal kidney tissue. These cells have been found to possess features characteristic of pluripotent stem cells, including rapid proliferation and the potential for differentiation into other cell lineages.
  • Multipotent kidney progenitor cells can give rise to multiple cell lineages, e.g ., renal cell lineages, adipocyte lineages, or osteoblast lineages.
  • Kidney progenitor cells demonstrate a gene expression profile for early developmental gene markers, kidney developmental gene markers, metanephric mesenchymal gene markers, and genes that promote the survival of metanephric mesenchyme.
  • kidney progenitor cells e.g . human kidney-derived cells
  • Tissue refers to a group or layer of similarly specialized cells, which together perform certain special functions.
  • Organic refers to two or more adjacent layers of tissue, which layers of tissue maintain some form of cell-cell and/or cell-matrix interaction to form a microarchitecture.
  • Kidney refers to one of a pair of organs in the abdomen. Kidneys remove waste from the blood (as urine), produce erythropoietin to stimulate red blood cell production, and play a role in blood pressure regulation. Kidneys function to maintain proper water and electrolyte balance, regulate acid-base concentration, and filter the blood of metabolic wastes, which are then excreted as urine.
  • Primary culture refers to a mixed cell population of cells that permits interaction of many different cell types isolated from a tissue.
  • the word “primary” takes its usual meaning in the art of tissue culture.
  • Capable of self-renewal and expansion in culture refers to mammalian kidney-derived cell populations that grow and divide in cell culture and maintain substantially the same phenotype as measured by cell markers and secretion of trophic factors from mother cell to daughter cell. At some point during replication of the mammalian kidney-derived cell population, the phenotype can change to a more specialized or differentiated state of the kidney-derived cell.
  • Cell culture refers generally to cells taken from a living organism and grown under controlled conditions, e.g., "in culture”.
  • a “primary cell culture” is a culture of cells, tissues or organs taken directly from organisms and before the first subculture. Cells are “expanded” in culture when they are placed in a growth medium under conditions that facilitate cell growth and/or division, resulting in a larger population of the cells. When cells are expanded in culture, the rate of cell proliferation is sometimes measured by the amount of time needed for the cells to double in number. This is referred to as "doubling time.”
  • a “cell line” is a population of cells formed by one or more subcultivations of a primary cell culture. Each round of subculturing is referred to as a passage. When cells are subcultured, they are referred to as having been "passaged.” A specific population of cells, or a cell line, is sometimes referred to or characterized by the number of times it has been passaged. For example, a cultured cell population that has been passaged ten times may be referred to as a "P10" culture.
  • the primary culture i.e., the first culture following the isolation of cells from tissue, is designated P0. Following the first subculture, the cells are described as a secondary culture (PI or passage 1).
  • the cells After the second subculture, the cells become a tertiary culture (P2 or passage 2), and so on. It will be understood by those of skill in the art that there may be many population doublings during the period of passaging; therefore the number of population doublings of a culture is usually greater than the passage number.
  • the expansion of cells (i.e., the number of population doublings) during the period between passaging depends on many factors, including, but not limited to the seeding density, substrate, medium, and time between passaging.
  • a “trophic factor” is defined as a substance that promotes survival, growth, proliferation, maturation, differentiation, and/or maintenance of a cell, or stimulates increased activity of a cell.
  • "Trophic support” is used herein to refer to the ability to promote survival, growth, proliferation, maturation, differentiation, and/or maintenance of a cell, or to stimulate increased activity of a cell.
  • the mammalian kidney-derived cell population of the present invention produces trophic factors, including but not limited to, growth factors, cytokines, and differentiation factors.
  • the trophic factors include, but are not limited to, FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, VEGF, MMP-2, or a combination thereof.
  • Non-immunogenic refers to cells or a cell population that does not elicit a deleterious immune response in a majority of treated mammalian subjects, that is an immune response that compromises the mammalian subject's health or that interferes with a therapeutic response in the treated mammalian subject.
  • Gene refers to a nucleic acid sequence encoding a gene product.
  • the gene optionally comprises sequence information required for expression of the gene (e.g., promoters, enhancers, etc.).
  • sequence information required for expression of the gene (e.g., promoters, enhancers, etc.).
  • genomic relates to the genome of an organism.
  • Gene expression data refers to one or more sets of data that contain information regarding different aspects of gene expression.
  • the data set optionally includes information regarding: the presence of target-transcripts in cell or cell-derived samples; the relative and absolute abundance levels of target transcripts; the ability of various treatments to induce expression of specific genes; and the ability of various treatments to change expression of specific genes to different levels.
  • Gene expression profile refers to a representation of the expression level of a plurality of genes without ( i.e., baseline or control), or in response to, a selected expression condition (for example, incubation of the presence of a standard compound or test compound at one or several timepoints). Gene expression can be expressed in terms of an absolute quantity of mRNA transcribed for each gene, as a ratio of mRNA transcribed in a test cell as compared with a control cell, and the like. It also refers to the expression of an individual gene and of suites of individual genes in a subject.
  • isolated refers to altered “by the hand of man” from the natural state i.e. anything that occurs in nature is defined as isolated when it has been removed from its original environment, or both. "Isolated” also defines a composition, for example, a mammalian kidney-derived cell population, that is separated from contaminants ( i.e. substances that differ from the cell). In an aspect, a population or composition of cells is substantially free of cells and materials with which it may be associated in nature.
  • isolated or “purified” or “substantially pure”, with respect to mammalian kidney-derived cells refers to a population of mammalian kidney-derived cells that is at least about 50%, at least about 75%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% pure, with respect to mammalian kidney-derived cells making up a total cell population.
  • the term "substantially pure” refers to a population of mammalian kidney-derived cells of the present invention that contain fewer than about 50%, preferably fewer than about 30%, preferably fewer than about 20%, more preferably fewer than about 10%, most preferably fewer than about 5%, of lineage committed kidney cells in the original unamplified and isolated population prior to subsequent culturing and amplification. Purity of a population or composition of cells can be assessed by appropriate methods that are well known in the art.
  • kidney-derived cells are cells that were isolated and obtained from the human kidney tissue.
  • the term also encompasses cells that were obtained ( e.g . isolated) from a tissue and then subsequently cultured.
  • the invention discloses a proximal tubule device comprising a decellularized biological scaffold and a renal proximal tubule cell epithelial monolayer formed from cells that are differentiable into renal cells.
  • the scaffold and cells together create a multi-component, two-dimensional proximal tubule device.
  • This renal proximal tubule cell epithelial monolayer is comprised of functioning proximal tubule cells.
  • proximal tubule devices of the invention optimally promote the functioning of natural regulative mechanisms of contact inhibition and the formation of an intact monolayer without use of inhibitors such as e.g. MEK inhibitors.
  • the proximal tubule devices of the invention also advantageously represent and/or mimic the underlying matrix that renal cells are typically exposed to in vivo.
  • the seeding on a natural decellularized scaffold allows the cells to differentiate and form epithelial monolayers, which are more stable than those produced via traditional methods.
  • the present invention describes a two-dimensional proximal tubule device that may be used as an in vitro testing system for transport studies, renal toxicity screening, or for screening the effects of therapeutic agents.
  • the two-dimensional bioartificial renal proximal tubule device is constructed by seeding a decellularized biological scaffold with kidney progenitor cells and, optionally, in some instances also microvascular endothelial cells, followed by static culture or culture in a bioreactor to allow differentiation of the kidney cells into functioning proximal tubule cells and maintain the assembled device for in vitro testing. These functioning proximal tubule cells form a monolayer on the surface of the scaffold.
  • the present invention also describes the use of decellularized biological scaffolds as a component of the described bioartificial proximal tubule device.
  • One or more of the surfaces of the decellularized biological scaffold may be seeded with cells.
  • the decellularized scaffold can be derived from any mammalian tissue, preferably portions of the alimentary canal, most preferably the stomach, duodenum, jejunum, ileum or colon.
  • the tissue from which the scaffold is derived is most preferably a portion of the jejunum.
  • the decellularized biological scaffold is derived from mucosal or submucosal tissue.
  • the decellularized biological scaffold is derived mammalian small intestine submucosa. The decellularized scaffolds, or pieces thereof, may be secured into devices that allow for seeding of each side of the scaffold surface.
  • the source tissue used for creating the decellularized scaffolds can be any mammalian tissue, including but not limited to human, primate, bovine, sheep, porcine, or rat tissue.
  • the tissue is isolated from the mammal.
  • the decellularized scaffolds are derived from mammalian cell cultures.
  • the source tissue is porcine tissue.
  • the scaffolds are derived from porcine tissues isolated from younger animals, such as e.g . younger animals less than 6 months old or animals less than 3 months old.
  • the scaffolds are derived from porcine tissues isolated from younger animals about 10 to 25 kg in weight, alternatively from about 10 to 20 kg in weight, and alternatively from about 15 to about 20 kg in weight.
  • scaffolds are derived from porcine tissues isolated from animals about 10 to about 15 kg in weight.
  • the mucosal structures of the isolated tissue are preserved during the isolation.
  • the mucosal structures are subsequently partially or fully removed to expose the submucosal layer for cell attachment.
  • the kidney progenitor cells are cultured on mucosal structures. It was observed that a higher percentage of kidney progenitor cells adopt an epithelial morphology when cultured on the submucosal structures compared to mucosal structures. Accordingly, in an alternate embodiment, the kidney progenitor cells are optimally cultured on submucosal structures.
  • cells differentiable into renal cells shall mean a precursor cell that differentiate into renal cells e.g. any progenitor, precursor, or primary cell that can differentiate into a renal cell.
  • cells can be selected from primary renal tubule epithelial cells, progenitor (e.g . stem) cells differentiated into renal cells or renal progenitor cells (such as e.g . inducible pluripotent stem cell), human kidney-derived cells, stem cells isolated from the kidney or progenitor cells isolated from the kidney, and mixtures thereof.
  • progenitor (e.g . stem) cells that can be differentiated in renal cells or renal progenitor cells may be used including, but not limited to, for example embryonic stem cells, iPS cells, umbilical-derived cells, placental-derived cells or mesenchymal stem cells.
  • the differentiable cells are mammalian kidney-derived cells.
  • one embodiment of the invention is the use of mammalian kidney-derived cells, isolated from the mammal's kidney (such as e.g. a human kidney), as a component of the described bioartificial renal system. It has previously been demonstrated, as described in U.S. Pub. App. 2008/0112939 to Colter et al. , that progenitor cells can be derived from human kidney tissue and that these kidney-derived cells can self-organize into tubule structure and can be used to treat a diseased kidney.
  • kidney-derived cells are isolated from a human kidney and suitable for organ transplantation.
  • blood and debris are removed from the kidney tissue prior to isolation of the cells by washing with any suitable medium or buffer such as phosphate buffered saline.
  • the kidney-derived cells such as e.g . human kidney-derived cells, are then isolated from mammalian kidney tissue by enzymatic digestion. Enzymes are used to dissociate cells from the mammalian ( e.g . human) kidney tissue.
  • dispase may be used.
  • combinations of a neutral protease (e.g . dispase), metalloprotease (e.g . collagenase) and hyaluronidase may be used to dissociate cells from the mammalian (e.g . human) kidney tissue. Isolated cells are then transferred to sterile tissue culture vessels that are initially coated with gelatin. Mammalian (e.g . human) kidney-derived cells are cultured in any culture medium capable of sustaining growth of the cells such as e.g., but not limited to, REGMTM renal epithelial growth medium (Lonza, Walkersville, MD) or ADVANCEDTM DMEM/F12 (Invitrogen).
  • the cells differentiable into renal cells may be a population of cells.
  • a population of human kidney-derived cells are used.
  • the population is homogenous.
  • the population is substantially homogenous.
  • the kidney-derived cells may be obtained from the kidney cortex, the kidney medulla or the kidney subcapsular region and mixtures thereof.
  • Mammalian (e.g . human) kidney-derived cells are characterized by phenotypic characteristics, for example, morphology, growth potential, surface marker phenotype, early development gene expression, kidney development gene expression and trophic factor secretion. Surface marker, gene expression and trophic factor secretion phenotype is retained after multiple passages of the human kidney-derived cell population in culture.
  • the isolated mammalian kidney-derived cells i.e. the cell populations
  • the cell populations are capable of self-renewal and expansion in culture and exhibit a unique expression profile, such as any of those described below.
  • the human kidney-derived cells are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5.
  • the cells are negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4.
  • the cells are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5 and negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2 or GATA-4.
  • the cell is positive for expression of at least one of Eyal, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR or Rex-1.
  • the cells are negative for expression of at least one of Sox2, FGF4, hTert or Wnt-4.
  • the cells are positive for expression of at least one of Eyal, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR or Rex-1, and negative for expression of at least one of Sox2, FGF4, hTert or Wnt-4.
  • the human kidney-derived cells are also positive for at least one of cell-surface markers HLA I, CD24, CD29, CD44, CD49c, CD73, CD166, or SSEA-4.
  • the human kidney-derived cells are also negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, or E-cadherin.
  • the human kidney-derived cells are also positive for at least one of cell-surface markers HLA I, CD24, CD29, CD44, CD49c, CD73, CD166, or SSEA-4, and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, or E-cadherin.
  • the human kidney-derived cells may secrete at least one of the trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF. In a preferred embodiment, the cells do not secrete at least one of trophic factors PDGFbb and IL12p70.
  • the progenitor cells used with the bioartificial proximal tubule device are human kidney-derived cells. These human kidney-derived cells are capable of self-renewal and expansion in culture and are positive for expression of at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7, or GDF5; and negative for the expression of at least one of Sox2, FGF4, hTert, Wnt-4, SIX2, E-cadherin or GATA-4.
  • the human kidney-derived cells may also be positive for at least one of cell-surface markers HLA-I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166, or SSEA-4; and negative for at least one of cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, and CD141.
  • these cells optionally cells secrete at least one of trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF; and do not secrete at least one of trophic factors PDGF-bb or IL12p70.
  • the human kidney-derived cells are (1) positive for expression of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7 and GDF5 and (2) negative for the expression of at least one of Sox2, FGF4, hTert, SIX2 and Gata-4.
  • the kidney-derived cells are (1) positive for expression of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7 and GDF5; (2) negative for the expression of at least one of Sox2, FGF4, hTert, SIX2 and Gata-4; (3) positive for cell-surface markers HLA I, CD24, CD29, CD44, CD49c, CD73, CD166, and SSEA-4; and (4) negative for HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD90, CD104, CD105, CD117, CD133, CD138, CD141, and E-cadherin.
  • the human kidney derived cells are capable of self-renewal and expansion in culture, positive for the cell surface marker expression HLA I and CD44, positive for the gene expression of Oct-4, Pax-2, and WT1, negative for the cell surface marker expression of CD133 and the gene expression of Wtn-4.
  • the human kidney derived cells are additionally positive for the gene expression of BMP7, BMP2, GDF4, EpoR and Rex-1, and negative for the gene expression of Sox2, FGF4 and hTert.
  • the human kidney-derived cells are: (1) capable of self-renewal and expansion of culture; (2) positive for the expression of HLA-I and at least one of Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7 or GDF5; and (3) negative for the expression of CD133 and at least one of SOX2, FGF4, hTert, Wnt-4, SIX2, E-cadherin or GATA-4.
  • These cells may further be (4) positive for at least one of the cell surface markers CD24, CD29, CD44, CD49c, CD73, CD90, CD166 or SSEA-A and (5) negative for at least one of the cell-surface markers HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, and E-cadherin.
  • These cells may also secrete at least one of the trophic factors FGF2, HGF, TGF ⁇ , TIMP-1, TIMP-2, MMP-2 or VEGF and lack secretion of at least one of trophic factors PDGFbb or IL12p70.
  • the human kidney-derived cells are a population.
  • Mammalian (e.g . human) kidney-derived cells are passaged to a separate culture vessel containing fresh medium of the same or a different type as that used initially, where the population of cells can be mitotically expanded.
  • the mammalian (e.g . human) kidney-derived cells are then seeded into the biological matrix, and cultured to allow differentiation of the kidney-derived cells into functioning proximal tubule cells.
  • the cells of the invention may be used at any point between passage zero and senescence.
  • the cells preferably are passaged between about 3 and about 20 times, between about 5 and about 10 times, between about 15 and 20 times, between about 5 and about 7 times, and more preferably between about 3 and about 7 times.
  • two or more surfaces of the decellularized biological scaffold are seeded with cells.
  • vascular endothelial cells are seeded on one surface of the scaffold, and the other surface is then seeded with mammalian kidney-derived cells.
  • the seeded scaffold is then cultured to allow differentiation of the kidney-derived cells into functioning proximal tubule cells and the formation of a vascular endothelial monolayer on the opposing surface.
  • the human vascular endothelial cells used for repopulation of the scaffold can be selected from endothelial cell lines, bone marrow or whole blood endothelial progenitor cells, or primary endothelial or microvascular endothelial cells.
  • the vascular endothelial cells used are isolated using conventional methods.
  • the cells used for repopulation of the scaffold are primary microvascular endothelial cells.
  • the vascular endothelial cells used can be isolated from any mammalian source.
  • the vascular endothelial cells isolated are of human origin.
  • the vascular endothelial cells are primary microvascular endothelial cells isolated from a mammalian (human) kidney.
  • Another embodiment of the invention is an apparatus for making the proximal tubule devices.
  • seeding of the decellularized scaffolds is accomplished by using a specially designed apparatus ("crown") in which a piece of the decellularized scaffold is inserted so its edges are placed between two pieces of metal or plastic, effectively sealing the edges to create an upper and lower well separated by the scaffold.
  • the crown also introduces some stretch and tension into the decellularized scaffold. Cells are then seeded into the upper well and allowed to settle onto the decellularized scaffold.
  • the crown can also be flipped over to allow seeding of the other side of the scaffold, or the crown and be disassembled, the scaffold turned over and reassembled into the crown for seeding of the opposite surface.
  • the renal cells may be seeded onto the scaffolds at a density ranging from about 500 cells/cm 2 to about 350,000 cells/cm 2 , alternatively from about 1,000 cells/cm 2 to about 100,000 cells/cm 2 , alternatively from about 750 cells/cm 2 to about 75,000 cells/cm 2 , alternatively from about 10,000 cells/cm 2 to about 300,000 cells/cm 2 , alternatively from about 7,500 cells/cm 2 to about 200,000 cells/cm 2 and preferably from about 5,000 cells/cm 2 to about 70,000 cells/cm 2 .
  • the cell-seeded scaffold with the apparatus is then cultured using conventional techniques to allow for differentiation of the renal cells and the formation of a continuous epithelial monolayer.
  • the time of culture may be from 1 to 6 weeks of culture, preferably 2 to 4 weeks of culture, most preferably 3 to 4 weeks.
  • the resulting mature proximal tubule device can then be used for renal transport studies, nephrotoxicity testing, or testing of therapeutic agents using conventional methods.
  • the culture of cells on the seeded scaffold, as well as the in vitro test system is achieved by placing the scaffolds in a custom designed bioreactor such that the scaffold creates a barrier between two compartments.
  • the bioreactor chamber is connected to a fluid flow system designed to allow fluid flow across both surfaces of the scaffold.
  • cell specific fluid mechanical conditions can be established for each side of the scaffold, depending on the cell type seeded, for example, to support the functionality of endothelial cells at the basolateral side.
  • the scaffolds may be pre-seeded with cells before placement into the bioreactor, or placed into the bioreactor followed by seeding of cells within the bioreactor.
  • the bioreactor is designed in a way such that the tension applied to the decellularized construct placed within the bioreactor can be altered as needed to facilitate the seeding and/or differentiation of cells.
  • the decellularized scaffold is seeded with cells using the apparatus described for seeding of renal cells and, optionally, endothelial cells.
  • the cell-seeded scaffolds are then removed from the apparatus and transferred to the bioreactor chamber for culture or assessments, as described below in the examples.
  • the cell-seeded scaffolds may be first cultured within the apparatus for a period of approximately 0 to 4 weeks before transfer to the bioreactor chamber.
  • the renal cells may be seeded onto the scaffolds at a density ranging from about 500 cells/cm 2 to about 350,000 cells/cm 2 , preferably about 5000 cells/cm 2 to about 70,000 cells/cm 2 .
  • the culture conditions, including the duration of incubation in the apparatus may vary depending on the source of the cell and the culture medium.
  • the decellularized scaffolds are first placed within a bioreactor chamber, and then scaffolds are seeded by perfusing a cell suspension into the bioreactor chamber and incubating for a period of time to allow cell attachment to the decellularized scaffold.
  • a bioreactor comprises an upper body element and a lower body element having an area designated for scaffold growth.
  • bioreactor 100 One exemplary bioreactor suitable for use in the instant invention is shown in Figure 15 .
  • the components of bioreactor 100 are the main body elements, upper body element 110 and lower body element 120, two clips, front clip 130 and back clip 160, the outer closure flaps, lower outer closure flap 140 and upper outer closure flap 150 and the connectors 170.
  • the main reactor upper body element 110 and lower body element 120 of bioreactor 100 are held together by front clip 130 and back clip 160.
  • Upper outer closure flap 150 is on top of the upper body element 110.
  • Lower outer closer flap 140 is below the lower body element 120.
  • Figure 16 is a view of the lower body element 120 of the bioreactor showing the groove 180 whose depth can be altered along with a frame in upper body element to adjust tension on the decellularized scaffold.
  • Lower body element 120 also contains the area for cell growth 190.
  • the unseeded scaffold can be positioned between upper body element 110 and lower body element 120 of the bioreactor 100 ( see Figure 15 ).
  • a circular frame construction which is milled into upper body element 110 with a corresponding groove structure in lower body element 120, allows the fixation of the scaffold comparable to the cell crowns.
  • the tension can be adjusted by using specifically designed frame/groove combinations, which differ in depth of the groove and bridge width of the frame.
  • the distance which the frame can be moved into the groove 180 determines the tension of the scaffold, with a longer distance leading to a higher tension. Factors like scaffold diameter and scaffold thickness must be considered.
  • front clip 130 and back clip 160 of the bioreactor keep upper body element 110 and lower body element 120 together and the construct can be handled like a cell crown.
  • Lower outer closure flap 140 and upper outer closure flap allow closure of the system and a cell suspension can be introduced to one side of the scaffold via the connectors 170 of the bioreactor.
  • the cells grow in cell growth area 190.
  • the closed bioreactor can be flipped over and a second or the same cell type can be seeded on the other side of the scaffold.
  • the cell suspensions used for seeding may range from about 10 3 cells/ml to about 10 7 cells/ml.
  • the compartment of the first side can be filled with media. If static conditions are required the compartment can be filled with cell culture media. Alternatively, perfusion of media under various flow conditions can be initiated using the connectors 170.
  • the cells can be cultured statically by simply flooding the chamber compartments with media and closing the connectors of the bioreactor.
  • tubes of a flow system are connected to the bioreactor and perfusion can be started.
  • Cells seeded onto decellularized scaffolds within the bioreactor chambers are then cultured to allow for growth and differentiation of the cells into a functional monolayer of renal tubular cells.
  • Culture of the cells may include static culture, or more preferably culture under dynamic conditions such as linear flow or pulsatile flow. Flow rates, pressure, and pulsatile conditions may all be varied to facilitate the growth and differentiation of the cells into functional renal cells.
  • the mean flow rate of media within the bioreactor may range from 1 to 25 ml/min, alternatively from about 1 to about 10 ml/min, alternatively from about 2.5 to about 10 m/min, alternatively from about 5 to 20 ml/min. In a preferred embodiment, the mean flow rate may range from about 2.5 to 15 ml/min.
  • the culture period may range from about 1 to about 4 weeks, alternatively from about 1 to about 2 weeks, alternatively from about 1 to about 3 weeks, alternatively from about 2 to about 4 weeks. In a preferred embodiment, the culture period may range from preferably about 2 to 3 weeks. During this time, the cell layer integrity can be monitored using techniques well-known in the art.
  • the cell layer integrity can be monitored by measuring the trans-epithelial electrical resistance using electrodes integrated in each compartment of the bioreactor or by measuring leakage across the monolayer of various fluorescently tagged molecules, such as e.g. inulin or creatinine.
  • different cell culture media are used in each chamber.
  • different flow rates, pressure, and pulsatile conditions may be used in each chamber allow cell specific cultivation via flow indices shear stress.
  • a description of the bioreactor can also be found in Patent Application No. DE 102008056037.5-41 and EP 2 184 344 .
  • Another embodiment of the invention is a method of differentiating the cells differentiable into renal cells (such as e.g. the mammalian (human) kidney-derived) cells into a stable monolayer of renal proximal tubule cells by differentiating the cells under tension.
  • This method may further comprise the use of the scaffolds of the invention to produce proximal tubule devices of the invention.
  • the proximal tubule devices of the invention may be used as in vitro testing systems for renal toxicity screening or for screening of therapeutic agents.
  • the devices may be used to monitor tubule cell function, such as transport, during or after exposure to a compound or particle.
  • Different media formulations can be used for the flow over each surface, allowing one to study transport across the cell and scaffold layers from one media compartment to the other.
  • One example of such media formulations would be to flow an endothelial cell media in the compartment that had the mvECs seeded on it, and to flow a media formulation that mimics the glomerular filtrate in the opposite compartment that contains the renal tubular monolayer.
  • Transport functions of the renal tubular monolayer can then be assessed using standard techniques and labeled molecules known by those skilled in the art.
  • Toxicity screening can be achieved by adding compounds or particles of interest to either the vascular compartment flow path that provides nutrients to and contacts the endothelial cells or by introducing compounds or particles to the tubule compartment flow path that provides nutrients to and contacts the renal tubular cells, mimicking the appearance of toxic xenobiotic compounds in the blood and urine, respectively.
  • Transport of compounds or particles can be monitored by assaying the medium of one or both of the flow paths.
  • toxicity can be monitored by assaying the cell viability, morphology, or effect on transport functions after exposure to the compounds of interest. Assays used for the assessment of toxicity or therapeutic effects of compounds or particles are not limited to those described above.
  • Therapeutic targets can be assayed by first injuring the kidney-derived cells of the bioartificial device, then treating the cells with the test therapeutic particle.
  • the injury can be introduced by physical or chemical means, such as e.g. exposing the cells to toxic compounds or particles, such as e.g. cisplatin or streptozotocin.
  • Test therapeutic compounds or particles can be put in contact with the cells by addition into the vascular compartment flow path of the device, for example, in a concentration that would mimic the concentrations cells would be exposed to after intravenous (IV) delivery of the therapeutic agent.
  • IV intravenous
  • Monitoring of renal tubular cell function can then be used to determine the degree of effectiveness of the applied test therapeutic compounds.
  • Monitoring tubular function includes, but is not limited to, detecting or assessing the uptake of a compound or particle by renal tubular cells, transport of a compound or particle taken up by the cells from one media compartment of the proximal tubule devices to the other, the effect of inhibitors on uptake or transport, and changes in renal tubule cell gene or protein expression, morphology, surface marker expression, enzymatic activity or survival. Assays used for the assessment of toxicity or therapeutic effects of compounds or particles are not limited to those described above.
  • kits comprising the bioartificial proximal tubule devices of the invention.
  • the kit comprises the bioartificial tubule device and a product insert.
  • An alternate embodiment of the invention is a composition comprising the bioartificial proximal tubule devices of the invention.
  • the composition comprises a bioartificial proximal tubule device of the invention and a pharmaceutically acceptable carrier.
  • kidney-derived cells useful in the devices and methods of the invention may be isolated and characterized according to the disclosure of U.S. Patent Publication No. 2008/0112939 , as it relates to the description, isolation and characterization of hKDC.
  • Example 1 Seeding and differentiation of hKDC on extracellular matrix scaffolds
  • hKDC human kidney-derived cells
  • hKDC at passage 4 were seeded onto three different scaffold configurations and on transwells (Corning, Corning NY). The cells were cultivated over a time period of three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville MD). Each scaffold configuration was tested with three different cell concentrations: 2.5 x 10 3 , 5 x 10 3 , and 1x10 4 cells. The configurations tested were: 1) collagen sandwich culture; 2) collagen-SIS sandwich culture; 3) SIS monolayer culture; and 4) collagen-coated transwells.
  • hKDC hKDC were cultivated between two collagen gel layers in 24-well plates.
  • the bottom gels were cast by first mixing a cold gel neutralization solution with collagen (type 1 isolated from rat tail tendons, 6 mg/ml in 0.1 % acetic acid) in a 1:2 ratio and then adding 500 ⁇ l of this solution per well.
  • the solution was gelled by incubation at 37 °C / 5 % CO 2 for 15 minutes.
  • the cells were seeded in 1 ml medium per well.
  • the cover gels were cast.
  • the medium was aspirated and 300 ⁇ l of gel solution (prepared as above) was pipetted into each well.
  • the solution was gelled by incubation for 15 minutes at 37 °C / 5 % CO 2 .
  • 1 ml medium was added per well.
  • Scaffolds were prepared by decellularizing segments of small intestine submucosa (SIS) using conventional methods. Briefly, the mucosa of segments of porcine small intestine was removed mechanically. Afterwards, decellularization was performed by incubating the intestinal segments in 3.4% sodium deoxycholate for 1 hour at 4 degrees Celsius with shaking. The decellularized segments were then rinsed extensively with PBS and sterilized by gamma irradiation. 12-well plates were used for the SIS monolayer cultures. Decellularized SIS was spanned over round metal frames and covered with 1 ml medium per well the day before seeding the cells. The spanned SIS surface is approximately equivalent to the surface of a well in a 24-well plate. To seed the cells onto the SIS, cell culture medium was removed and the appropriate amount of cells was seeded in 1 ml of medium per well.
  • SIS small intestine submucosa
  • SIS scaffolds were prepared and seeded with hKDCs as described above. After allowing the cells to attach for 24 hours, a cover gel was cast over the cells as in the collagen sandwich cultures ( see above).
  • Transwells were transferred into 12 well plates and coated, each with 200 ⁇ l collagen type 1 (100 ⁇ g/ml in 0.1 % acetic acid). The coating solution was incubated for 20 minutes at room temperature and then aspirated. The appropriate amount of cells was seeded in 1.5 ml medium per well.
  • immunohistochemistry was performed to characterize the differentiation of the cells using the following antibodies: Anti-hPAX2, Anti-hAQP1, Anti-Ki67, Anti hE-cadherin and Anti-hN-cadherin ( see Table 1 below).
  • Anti-hPAX2, Anti-hAQP1, Anti-Ki67, Anti hE-cadherin and Anti-hN-cadherin see Table 1 below.
  • 3 ⁇ m cross sections were deparaffinized.
  • Target retrieval was achieved by either enzymatic treatment with proteinase K or by heating in citrate buffer pH 6 (Dako, #S2369) or Tris/EDTA buffer pH9 (Dako, #S2367).
  • a blocking step with 3% hydrogen peroxidase was included to block endogenous peroxidases.
  • hKDC cultured on transwells with collagen-coated PET membranes show a flat morphology, multilayer formation and agglomerates that were observed to peel off the surface, which leads to a non-continuous cell layer.
  • These observed properties of the hKDC on collagen-coated PET membranes make them unsuitable for transport assays.
  • Similar multi-layering has also been observed with polyester and polycarbonate transwell membranes, indicating that this effect is a property of synthetic membranes in general, not the specific membranes used in the experiment. These properties were not observed for the SIS culture, which implies that this scaffold promotes the functioning of natural regulative mechanisms of contact inhibition and the formation of an intact monolayer.
  • Aquaporins catalyze the transport of water through the cell membrane and are thus very important for kidney functionality.
  • Aquaporin 1 is expressed by proximal kidney cells whereas Aquaporin 2 is predominant in distal tubule cells.
  • Aquaporin 1 expression could be detected after 2 and 3 weeks of culture whereas Aquaporin 2 expression was not observed.
  • the staining of Aquaporin-1 was observed to be only on the apical side of the cuboidal cells ( see Figure 9 ) again indicating a mainly proximal differentiation of the cells.
  • SGLT-1 sodium glucose co-transporter 1
  • hKDCs are able to differentiate into proximal tubule cells, and that this differentiation is dependent on the composition of the substrate onto which the cells are seeded.
  • a planar natural extracellular (i.e. decellularized) matrix outperformed collagen, SIS/collagen scaffolds as well as standard transwell culture with regard to hKDC epithelial morphology and differentiation.
  • Non-transformed proximal tubule cells typically will continue to grow once confluence is reached, resulting in the formation of three-dimensional aggregates on synthetic planar surfaces such as transwells. Seeding on a natural decellularized scaffold, such as SIS, allows the cells to differentiate and form epithelial monolayers that are more stable than those produced via traditional methods.
  • Example 1 demonstrated that cells seeded onto two-dimensional decellularized scaffolds without collagen formed a confluent epithelial monolayer expressing proximal tubule markers after three weeks of culture. The following experiments were conducted to optimize the cell seeding density and attempt to reduce the culture period necessary for formation of the monolayer.
  • Scaffolds were prepared by decellularizing segments of small intestine submucosa (SIS) as described in Example 1.
  • SIS small intestine submucosa
  • hKDC at passage 4 were seeded onto the SIS scaffolds at three different concentrations (1 x 10 4 , 5 x 10 4 , and 1 x 10 5 cells/well) and cultivated for three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville). Samples were removed for histological analysis after two and three weeks and were fixed with Bouin's fixative for 1 hour. Thereafter they were washed in water for at least 4 hours and embedded into paraffin. Subsequently, 3 ⁇ m thick slices were prepared.
  • the slices were stained with hematoxylin and eosin (H&E) to assess cell morphology.
  • immunohistochemistry IHC was performed, as in Example 1, to characterize the differentiation of the cells.
  • 3 ⁇ m cross sections were deparaffinized.
  • Target retrieval was achieved by enzymatic treatment with proteinase K, by heating in citrate buffer pH 6 (Dako, #S2369) or by heating in Tris/EDTA buffer pH 9 (Dako, #S2367).
  • a blocking step with 3 % hydrogen peroxidase was included to block endogen peroxidases.
  • Primary antibodies were then incubated for 1 hour followed by their detection with the ENVISIONTM Detection System Peroxidase/DAB Rabbit/Mouse (Dako, #K5007).
  • the slices were counterstained with hematoxylin.
  • Lectin staining was performed to further evaluate cell differentiation. As described above, 3 ⁇ m cross sections were deparaffinized and blocked with hydrogen peroxidase. Biotinylated lectins, either Lotus tetragonobolus lectin (Biozol, #B-1325) or Dolichos biflorus agglutinin (Biozol, #B1035), were then incubated for 1 hour, followed by labeling with streptavidin (Biogenex, #LP000-ULE) and detection by addition of aminoethyl carbazole chromogen (AEC) (Biogenex, #HK129-5KE). Slices were counterstained with hematoxylin.
  • LTL Lotus tetragonobulus lectin
  • DBA Dolichos biflorus agglutinin
  • the sample seeded at 1 x 10 4 cells/well was also analyzed for the expression of collagen type IV by immunohistochemistry, as described above, using anti-human collagen IV antibody (Dako, #M0785).
  • the results, shown in Figure 11 demonstrate positive staining of collagen IV on the basolateral surface of the cells, indicating that the cells were actively secreting extracellular matrix components on the decellularized natural scaffold; demonstrating that intact monolayers can be developed on decellularized natural scaffolds, which are more physiologically relevant than synthetic scaffolds, such as transwells. Further, it suggests that the cell seeding density has a direct effect on cell differentiation and monolayer formation.
  • Table 2 Immunohistochemistry results in relation to initial seeding density after various time periods of culture.
  • Scaffolds were prepared by decellularizing segments of small intestine submucosa (SIS) as described in Example 1.
  • SIS small intestine submucosa
  • hKDC at passage 4 were seeded onto the SIS scaffolds at 5 x 10 4 cells/scaffold and cultivated for three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville). Samples were removed for histological analysis after three weeks and fixed with Bouin's fixative for 1 hour. Afterwards, they were washed in water for at least 4 hours and embedded into paraffin. Subsequently, 3 ⁇ m thick slices were prepared.
  • Immunohistochemistry was performed to confirm the expression of p-glycoprotein-1 (pgp-1 aka MDR1), which is an efflux transporter expressed by proximal tubule cells.
  • Target retrieval of deparaffinized sections was achieved by enzymatic treatment with proteinase K, by heating in citrate buffer pH 6 (Dako, #S2369), or by heating in Tris/EDTA buffer pH 9 (Dako, #S2367).
  • a blocking step with 3 % hydrogen peroxidase was included to block endogen peroxidases.
  • Results showed positive staining for pgp-1 on the apical membrane of the cellular monolayer ( see Figure 13 ), confirming expression of a functional marker of proximal tubule cells, further indicating that the scaffold and seeding methods described allow for differentiation of hKDCs into functioning proximal tubule cells.
  • Example 4 Albumin uptake by hKDCs seeded on decellularized scaffolds
  • Scaffolds were prepared by decellularizing segments of small intestine submucosa (SIS) as described in Example 1.
  • SIS small intestine submucosa
  • hKDC at passage 4 were seeded onto the SIS scaffolds at 5 x 10 4 cells/scaffold and cultivated for three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville).
  • REGMTM renal epithelial growth medium Lionza, Walkersville
  • cell-seeded samples were first pre-incubated in serum-free medium (REBM basal medium, Lonza, Walkersville) for 1 hour. The media was then exchanged with REBM basal medium containing 200 ⁇ g/ml fluorescently labeled bovine serum albumin (BSA-FITC) (Sigma, #A9771) and incubated for 30 to 60 minutes. The samples were then washed with PBS, counterstained with DAPI (diamidino-2-phenylindole) and imaged on a fluorescent microscope.
  • Examples 5 to 9 that follow are prophetic Examples designed to further elucidate properties for the scaffolds of the invention.
  • Functional assays such as BSA-FITC uptake, can be used to assess cellular injury or nephrotoxicity, as well as the effectiveness of therapeutic compounds on the restoration of renal transport functions.
  • Example 5 Organic anion transport by hKDCs seeded on decellularized scaffolds
  • This example tests function of organic anion transporters, as well as pgp-1, an efflux transporter, by assaying transport of fluorescent dyes, such as rhodamine, lucifer yellow, or carboxyfluorescein. Transport into the cell is mediated by various organic anion transporters (OATs). When the pgp-1 transporter is inhibited by verapamil, applied dye such as rhodamine ceases to be transported out of the cell, resulting in an increase in cellular fluorescence.
  • OATs organic anion transporters
  • Scaffolds will be prepared by decellularizing segments of small intestine submucosa (SIS) as described in Example 1.
  • SIS small intestine submucosa
  • hKDC at passage 4 will be seeded onto the SIS scaffolds at 5 x 10 4 cells/scaffold and cultivated for three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville).
  • REGMTM renal epithelial growth medium Lionza, Walkersville
  • the media in the top compartment will then be exchanged with phenol-red free medium containing various concentrations of rhodamine, lucifer yellow or carboxyflourescein dye.
  • Some wells will also be pre-incubated with various concentrations of verapamil in both compartments prior to the addition of the media containing the fluorescent dye (with and without additional verapamil in the medium) to the top compartment.
  • the wells will then be incubated for 30 to 120 minutes.
  • the samples will be then washed with PBS, fixed, counterstained with DAPI and imaged on a fluorescent microscope.
  • samples of the medium will be taken for quantitative analysis of the presence of fluorescent dye.
  • Example 6 Seeding and differentiation of hKDCs (with or without microvascular endothelial cells) on decellularized scaffolds within a flow bioreactor.
  • the bioreactor system will be prepared as described above.
  • the scaffold is positioned between upper body element 110 and lower body element 120 of bioreactor 100 and fixated with a tension comparable to the cell crowns ( see Figure 15 ).
  • the tension on the scaffold positioned in the bioreactor can be altered and experiments will be conducted to determine the tension ranges most appropriate for formation of a monolayer of cells and subsequent differentiation.
  • One side of the scaffold will be seeded with hKDCs followed by an appropriate adherence period (without flow).
  • the other side of the scaffold may then be seeded with endothelial cells.
  • the bioreactor chambers will then be perfused after an appropriate period of cell adhesion.
  • the flow rate will be adjusted to renal conditions to promote differentiation and epithelial monolayer formation. Monolayer formation and integrity will be monitored by periodic measurement of trans-epithelial electric resistance (TEER) as well as by measuring leakage of fluorescent FITC-inulin. In cases where both cell types are used, the flow conditions will be adjusted to those appropriate for maintenance of both epithelial and endothelial cell monolayers. In addition to TEER and inulin monitoring, samples will be fixed after 1, 2 and 3 weeks. Epithelial morphology and monolayer formation will be evaluated by hematoxylin and eosin staining.
  • TEER trans-epithelial electric resistance
  • Example 7 Functional transport of glucose and reabsorption of other solutes by hKDCs (with or without microvascular endothelial cells) seeded on SIS scaffolds and cultured within a flow bioreactor
  • This example demonstrates functional differentiation of hKDCs into proximal tubule epithelial cells when seeded onto SIS scaffolds in a flow bioreactor by analyzing active transport of glucose and other solutes from one media compartment across the cell-seeded membrane to another media compartment.
  • SIS scaffolds will be prepared as described in Example 1.
  • Microvascular endothelial cells mvEC
  • hKDCs will subsequently be seeded onto the other side of the scaffolds.
  • the scaffolds will then be placed into bioreactor chambers, which allow for media flow across each side of the scaffolds, and cultured to allow monolayer formation as in Example 6.
  • Monolayer formation will be monitored by TEER measurement and FITC-inulin leakage as in Example 6. At this point, each media compartment is enclosed in a small loop, which is separated only by the intact cell monolayers on the SIS scaffold.
  • media containing known concentrations of glucose will be used in the different media compartments with or without the addition of a glucose transport inhibitor such as e.g. phloridzin.
  • the media will be allowed to flow across the mature cell monolayers for a period of approximately 48 hours, with media samples being periodically removed for glucose concentration measurements via a colorimetric assay.
  • Multiple experiments will be conducted with differing glucose concentrations in the two compartments in order to examine the change in glucose concentrations with time. Results from these measurements will be used to calculate the relative amount of glucose transport vs. consumption by the cells with respect to time. Similar experiments can be conducted with other solutes that are either transported or taken up and degraded by the cells, such as e.g. albumin.
  • Vitamin D activation is a specific function of proximal tubule cells of the kidney. Accordingly, this example tests for vitamin D activation by testing the activity of 25-(OH)D 3 -12-hydroxylase enzyme which converts the inactive 25-OH-D 3 precursor into its active 1,25-(OH) 2 D 3 form.
  • hKDC will be seeded on SIS, which will be prepared as described in Example 1.
  • hKDC at passage 4 will be seeded onto the SIS scaffolds at 5x104 cells/scaffold and cultivated for three weeks with REGMTM renal epithelial growth medium (Lonza, Walkersville).
  • the medium will be exchanged to a medium containing the inactive 25-OH-D 3 precursor. After an incubation time of approximately 15 minutes to 2 hours, the medium will be collected and analyzed for the amount of both precursor and the active 1,25-(OH) 2 D 3 form by HPLC analysis or ELSIA.
  • the incubation time may be varied depending on incubation medium and incubation temperature.
  • the conversion can be further induced by the addition of parathyroid hormone or inhibited by phosphate addition.
  • Example 9 hKDC/SIS Renal Proximal Tubule System for Nephrotoxicity Testing and Drug Discovery Applications
  • nephrotoxic substances e.g . cisplatin, vinblastin
  • renoprotective reagents will be applied on the hKDC/SIS renal proximal tubule model system.
  • hKDCs will be seeded onto SIS, under static and/or flow conditions and allowed to grow and differentiate into a monolayer of proximal tubule epithelium.
  • various nephrotoxic substances will be applied to the hKDC/SIS system and cell viability, morphology and proximal tubule functionality will be evaluated.
  • Renal functional parameters include, e.g.
  • hKDC proximal tubule system will be tested for its ability to detect the effects of various renoprotective and other cytoprotective reagents.
  • DMEM-low glucose Invitrogen, Carlsbad, CA
  • PBS phosphate buffered saline
  • GMP manufacturing practice
  • NB6, N0002779, Serva Electrophoresis GmbH, Heidelberg, Germany 2.5 units/milliliter dispase
  • Dispase II 165 859 Roche Diagnositics Corporation, Indianapolis, IN
  • 1 unit/milliliter hyaluronidase Vitrase, ISTA Pharmaceuticals, Irvine, Ca
  • non-GMP grade enzyme mixtures containing 500 units/milliliter collagenase (Sigma, St Louis, MO), 50 units/milliliter dispase (Invitrogen) and 5 units/milliliter hyaluronidase (Sigma).
  • Kidney-derived cells were also isolated with 50 units/milliliter dispase.
  • the enzyme mixture was combined with either renal epithelial growth medium (REGM) (Cambrex, Walkersville, MD) or mesenchymal stem cell growth medium (MSCGM) (Cambrex).
  • REGM renal epithelial growth medium
  • MSCGM mesenchymal stem cell growth medium
  • the conical tubes containing the tissue, medium and digestion enzymes were incubated at 37°C in an orbital shaker at 225 rpm for 1 hour.
  • the digest was centrifuged at 150 x g for 5 minutes and the supernatant was aspirated.
  • the resulting cell pellet was resuspended in 20 milliliters of REGM or MSCGM.
  • the cell suspension was filtered through a 40-micron nylon BD FALCON cell strainer (BD Biosciences, San Jose, CA).
  • the filtrate was resuspended in medium (total volume 50 milliliters) and centrifuged at 150 x g for 5 minutes.
  • the supernatant was aspirated and the cell pellet was resuspended in 50 milliliters of fresh culture medium. This process was repeated twice more.
  • the supernatant was aspirated and the cell pellet was resuspended in 5 milliliters of fresh culture medium.
  • the number of viable cells was determined using a Guava instrument (Guava Technologies, Hayward, CA). Cells were then plated at a seeding density of 5000 cells/cm 2 onto 2% gelatin or laminin coated tissue culture flasks and cultured either in a low oxygen (hypoxia) or normal (normoxia) atmosphere.
  • Table 1 shows the donor information and growth conditions used to isolate populations of kidney-derived cells. To obtain single-cell derived clones of kidney cells, limiting dilution techniques were performed. In total, cells were isolated using twenty-four different conditions, from four different cadaveric donors ages 39, 46, 21 and 10 years old.
  • kidney-derived cell populations were assessed by light microscopy and morphological characteristics of the cells were observed. Consistently, all isolation conditions gave rise to cells with an epithelial morphology. (see Table 11-1). Table 11-1: Conditions used to establish cultures of kidney-derived cells.
  • kidney-derived cells can be isolated from a donor of any age or gender, as well as isolated using various growth media formulations or culture conditions. The ease and consistency of the isolation procedure shows that kidney-derived cells are a valuable source of cells for use in cell-based therapies.
  • Kidney-derived cells can be extensively propagated in culture and are able to generate significant numbers of cells in a short time. This is a criterion for the development of allogeneic cell therapies.
  • Kidney-derived cells were plated at 5,000 cells/cm 2 onto T75 flasks in REGM or MSCGM and cultured at 37°C in 5% carbon dioxide. Cells were passaged every 2-5 days. At each passage, cells were counted and viability was measured using a Guava instrument (Guava Technologies, Hayward, CA). Cell populations were continually passaged for several weeks until senescence was reached. Senescence was determined when cells failed to achieve greater than one population doubling during the study time interval. Population doublings [ln(final cell yield/initial number of cells plated)/ln2] were then calculated.
  • kidney-derived cells from isolations 22 and 23, were plated into T25 flasks and allowed to attach overnight. Flasks were then filled with REGM and karyotype analysis was performed.
  • Table 12-1 is a summary of the growth data for isolations tested. There was no noticeable effect on the cell growth characteristics with regards to donor age, tissue source, or enzymes used to isolate the cells.
  • Table 12-1 Summary of growth potential data. Population doublings (PD). Refer to Table 11-1 for isolation number cross-reference. Isolation Days until senescence Passage PD Viability (%) 1 54 12 31.2 98 2 54 12 26.8 98 17 51 11 30.2 98 18 48 10 26.8 97 19 42 9 24.9 97 20 48 10 31.0 98 21 48 10 29.0 98 22 47 16 28.7 97 23 47 16 27.9 97
  • kidney-derived cells have a robust growth potential in culture. These data can be used to estimate the total number of cells generated from one whole human kidney. If all of the kidney tissue was processed, and the resulting cells were cultured for 31 population doublings, one whole human kidney would yield an estimated 1.89 x10 16 total cells. Therefore, considering that one therapeutic dose of cells is 1 x 10 8 cells per person, kidney-derived cells, isolated from a single kidney will be sufficient to treat 189 million patients. Ultimately, these cells are a highly expandable source of cells for use in allogeneic-based cell therapies.
  • Flow cytometric analysis was performed on human kidney-derived cells to determine the surface marker phenotype.
  • Cells from 9 of the isolations in Example 11 were expanded to passage 4 and passage 10 in REGM on T75 flasks at 37°C and 5% carbon dioxide.
  • Adherent cells were washed in PBS and detached with TrypLE Select (Gibco, Grand Island, NY). Cells were harvested, centrifuged and resuspended in 3% (v/v) FBS in PBS at a concentration of 2 x 10 5 cells/milliliter.
  • the specific antibody was added to 100 microliters of cell suspension and the mixture was incubated in the dark for 30-45 minutes at 4°C. After incubation, cells were washed with PBS and centrifuged to remove excess antibody.
  • Table 13-2 shows a summary of all surface marker phenotype data. All isolations tested showed positive staining for CD24, CD29, CD44, CD49c, CD73, CD166, SSEA-4 and HLA I and negative staining for CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138, CD141, E-cadherin and HLA II. In addition, all isolations analyzed were expanded for multiple generations (passage 10) and still retained their surface marker phenotype.
  • kidney-derived cells express HLA I, but do not express HLA II, CD80 or CD86. These cell expression characteristics reflect the cell's ability to evade a host immune system. These data demonstrate that kidney-derived cells are non-immunogenic and can be administered to a patient without the need for tissue typing or immunosuppression.
  • kidney-derived cells from multiple donors can be isolated under various conditions ( see Table 11-1) and still maintain their surface marker phenotype.
  • they express putative progenitor markers such as CD24 and SSEA-4, yet do not express mature, lineage-committed markers such as E-cadherin.
  • kidney-derived cells are non-immunogenic and therefore are an attractive source of cells for use in allogeneic cell therapies.
  • Table 13-2 Summary of surface marker analysis. Not determined (ND). Positive staining (+). Negative staining (-).
  • Table 14-1 Primers used in the study Gene SuperArray catalogue number Oct-4 PPH02394A Rex 1 PPH02395A Sox2 PPH02471A Human TERT (hTERT) PPH00995A FGF4 PPH00356A Pax 2 PPH06881A Cadherin-11 PPH00667A WT1 PPH00254A FOXD1 PPH01990A WNT4 PPH02445A Epo PPH01338A EpoR PPH02642A Eya1 PPH10542A HNF3B PPH00976A Sox17 PPH02451A Gata4 PPH010860A Six2 PPH10860A CXCR4 PPH00621A BMP-2 PPH00549A BMP-7 PPH00527A GDF5 PPH01912A
  • PCR was performed using an ABI Prism 7000 system (Applied Biosystems, Foster City, CA). Thermal cycle conditions were initially 50°C for 2 min and 95°C for 10 min followed by 34 cycles of 95°C for 15 sec and 60°C for 1 min.
  • PCR was performed using GAPDH primers from Applied Biosystems (cat#: 402869) 1 microliter of cDNA solution and 1 ⁇ AmpliTaq Gold universal mix PCR reaction buffer (Applied Biosystems, Foster City, CA) according to manufacturer's instructions.
  • Primer concentration in the final PCR reaction was 0.5 micromolar for both the forward and reverse primer and the TaqMan probe was not added.
  • Samples were run on 2% (w/v) agarose gel and stained with ethidium bromide (Sigma, St. Louis, MO). Images were captured using a 667 Universal Twinpack film (VWR International, South Plainfield, NJ) and a focal-length PolaroidTM camera (VWR International, South Plainfield, NJ). For each gene analyzed, the final PCR product was excised from the gel and target sequence was confirmed by DNA sequencing.
  • RT-PCR analysis was performed on isolations 1, 2, and 17-23 in order to detect the expression of early developmental gene marker (Oct-4, Rex-1, Sox2, FGF4, hTert), kidney developmental gene markers (Pax-2, WT-1, Eya-1, Wnt-4, BMP-7, Cadherin-11, FoxD1), metanephric mesenchymal gene markers (Pax-2, Eya-1, WT-1, Six2, and FoxD1), and genes that promote the survival of metanephric mesenchyme (BMP-7).
  • early developmental gene marker Oct-4, Rex-1, Sox2, FGF4, hTert
  • kidney developmental gene markers Pax-2, WT-1, Eya-1, Wnt-4, BMP-7, Cadherin-11, FoxD1
  • metanephric mesenchymal gene markers Pax-2, Eya-1, WT-1, Six2, and FoxD1
  • BMP-7 metanephric me
  • kidney-derived cells express genes involved in early development and kidney development. They express markers for metanephric mesenchyme and markers for renal progenitor cells. They express endodermal markers as well as factors involved in renal repair and tubulogenesis.
  • kidney-derived cells are a source of putative renal progenitor cells that can be used for cell-based therapies to protect or repair damaged kidney tissue.
  • Kidney-derived cells were shown to consistently produce trophic factors that protect and repair the kidney. Therefore, these cells may serve as a therapeutic agent for treating kidney disease.
  • Passage 3 cells, from isolations 17-21 were seeded at 5,000 cells/cm 2 in one T75 flask/isolation, each containing 15 milliliters of REGM. Cells were cultured at 37°C in 5% carbon dioxide. After overnight culture, the medium was changed to a serum-free medium (DMEM-low glucose (Gibco), 0.1% (w/v) bovine serum albumin (Sigma), penicillin (50 units/milliliter) and streptomycin (50 micrograms/milliliter) (Gibco)) and further cultured for 8 hours. Conditioned, serum-free medium was collected at the end of incubation by centrifugation at 14,000 x g for 5 min and stored at -20°C.
  • DMEM-low glucose (Gibco) 0.1% (w/v) bovine serum albumin (Sigma), penicillin (50 units/milliliter) and streptomycin (50 micrograms/milliliter) (Gibco)
  • tissue inhibitor of metalloproteinase-1 tissue inhibitor of metalloproteinase-2
  • PDGF-bb platelet-derived epithelial growth factor
  • KGF keratinocyte growth factor
  • HGF hepatocyte growth factor
  • FGF2 basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • MCP-1 interleukin-6
  • IL-8 transforming growth factor alpha
  • TIMP-1 The secretion of twenty-seven different growth factors and cytokines were analyzed on isolations 17-21. The results are summarized in Table 15-1. All isolations secreted TIMP-1, TIMP-2, VEGF, and MMP-2 at over 300 picograms/milliliter/1x10 6 cells/8 hours. They secreted 50-300 picograms/milliliter/1x10 6 cells/8 hours of FGF2 and HGF and 1-50 picograms/milliliter/1x10 6 cells/8 hours of KGF, PDGF-bb, b-NGF, IL-12p40 and IL-11. SDF-1, ANG-2, HGH and Il-12p70 were not detected.
  • kidney-derived cells secrete several trophic factors for protecting and repairing damaged kidney tissue.
  • FGF2, HGF, and TGF ⁇ have been implicated in renal repair.
  • Kidney-derived cells secrete these factors at elevated and consistent levels. Therefore, these cells are a valuable source of cells for use in therapies targeting kidney diseases.
  • Kidney-derived cells can be thawed at passage 4 and passage 10 and then triturated into a single-cell suspension at 4 x 10 4 cells/milliliter in a type I collagen solution containing 66% vitrogen 100 (3 milligrams/milliliter (Cohesion Technologies, Palo Alto, CA). Cells in suspension can be plated onto a de-cellularized omentum membrane. The collagen/cell mixture can then be incubated for 30 minutes at 37°C, 5% CO 2 , 95% air to allow the collagen to gel and then culture medium is added. Cells are fed every 3 days for 7 days. On day 7, cultures are treated with varying concentrations of hepatocyte growth factor and further cultured until tubulogenesis is observed.
  • kidney-derived cells can self-organize into tubule structures in vitro. These structures have value as building blocks for kidney reconstruction applications as well as for developing drug screening and toxicology assays.
  • 35/65 PCL/PGA (10 cm diameter x 2 mm thickness) films were seeded with human kidney-derived cells (10,000cells/cm 2 ) and cultured in REGM (Cambrex) at 37°C and 5% carbon dioxide for 8 days.
  • the 35/65 PCL/PGA foam scaffold was prepared according to the methods described in U.S. patent 6,355,699 , incorporated herein by reference in its entirety.
  • the cell/film constructs were then removed from the film-casting dish, stacked into three layers and applied to a 35/65 PCL/PGA foam scaffold support. This construct was then cultured for an additional 24 hours and then cut into 3 x 3 mm square pieces prior to implantation. The implants were then washed with PBS and transferred to a 6-well plate filled with PBS for transport.
  • the implants were subcutaneously implanted bilaterally in the dorsal lateral thoracic-lumbar region of SCID mice.
  • Male SCID mice (Fox Chase SCID CB17SC strain) were purchased from Taconic Inc., (Hudson, NY). and were 5 weeks old.
  • Two implants were placed in each SCID mouse.
  • Two skin incisions, each approximately 5 mm in length, were made on the dorsum of the mice. The incisions were placed transversely over the lumbar area about 5 mm cranial to the palpated iliac crest, with one on either side of the midline.
  • the skin was then separated from the underlying connective tissue to make a small pocket, and the implant was placed about 10 mm cranial to the incision.
  • the skin incisions were closed with Reflex 7 metal wound clips. After 3 weeks, the implants were removed from the subcutaneous pocket, fixed in 10% formalin, embedded in paraffin wax, sectioned, stained with hematoxylin and eosin (H&E) and evaluated by a pathologist using light microscopy techniques.
  • H&E hematoxylin and eosin
  • Kidney-derived cells formed tubule-like structures within the layers of PCL/ PGA film. These tubules showed a distinct epithelial wall and a clear lumen. Kidney-derived cells infiltrated the foam scaffold, deposited extracellular matrix, and formed a dense, tissue-like structure. In addition, kidney-derived cells within the foam stimulated angiogenesis and the formation of vascular networks.
  • kidney-specific cells formed tubule structures after exposure to an in vivo microenvironment.
  • the ability of kidney-derived cells to respond to microenvironmental signals and to instruct the cells to form tubules further illustrates the renal progenitor nature of these cells.
  • the cells migrated into the foam scaffolds, forming a tissue-like structure that promoted angiogenesis. This data illustrates the utility of kidney-derived cells as cellular building blocks for reconstructing kidney tubules and ultimately for use in kidney tissue engineering applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)

Claims (13)

  1. Bioartifizielle proximale Tubulusvorrichtung, umfassend ein dezellularisiertes biologisches Matrixgerüst, das aus einem Säugetiergewebe gewonnen wurde und mit einer oder mehreren Präkursorzellen unter Bedingungen beimpft ist, die dazu ausreichen, die Differenzierung der Präkursorzelle in proximale Nierentubulusepithelzellen zu ermöglichen, wobei die differenzierten Zellen eine Epithelmonoschicht an dem Gerüst bilden, und wobei die eine oder die mehreren Präkursorzellen aus der Gruppe bestehend aus primären Nierentubulusepithelzellen, induzierbaren pluripotenten Stammzellen, Nierenprogenitorzellen, in Nierenzellen oder Nierenprogenitorzellen differenzierten Progenitorzellen, aus der Niere isolierten Stammzellen oder aus der Niere isolierten Progenitorzellen und Gemischen davon ausgewählt sind, wobei das dezellularisierte biologische Matrixgerüst aus dem mukosalen oder submukosalen Gewebe gewonnen wird, oder wobei
    das dezellularisierte biologische Matrixgerüst aus einem Säugetierverdauungskanal gewonnen wird.
  2. Bioartifizielle proximale Tubulusvorrichtung, umfassend ein dezellularisiertes biologisches Gerüst, das aus einem Säugetiergewebe gewonnen wurde und mindestens zwei Oberflächen aufweist, wobei mindestens eine Oberfläche mit einer oder mehreren Präkursorzellen unter Bedingungen beimpft ist, die dazu ausreichen, eine Differenzierung der Zellen in proximale Nierentubulusepithelzellen zu ermöglichen, wobei die Zellen eine Epithelmonoschicht auf der Oberfläche des Gerüsts bilden, und wobei die eine oder die mehreren Präkursorzellen aus der Gruppe bestehend aus primären Nierentubulusepithelzellen, induzierbaren pluripotenten Stammzellen, Nierenprogenitorzellen, in Nierenzellen oder Nierenprogenitorzellen differenzierten Progenitorzellen, aus der Niere isolierten Stammzellen oder aus der Niere isolierten Progenitorzellen und Gemischen davon ausgewählt sind; wobei
    das dezellularisierte biologische Matrixgerüst aus einem mukosalen oder submukosalen Gewebe gewonnen wird,
    oder wobei
    das dezellularisierte biologische Matrixgerüst aus einem Säugetierverdauungskanal gewonnen wird.
  3. Verfahren zum Differenzieren von einer oder mehreren Präkursorzellen in Nierenzellen, das das Beimpfen eines dezellularisierten biologischen Matrixgerüstes, das aus Säugetiergewebe mit einer oder mehreren Präkursorzellen gewonnen wurde, und das Kultivieren der Zellen an dem Gerüst unter Bedingungen umfasst, die dazu ausreichen, die Differenzierung der Präkursorzelle in proximale Nierentubulusepithelzellen zu ermöglichen, wobei die differenzierten Zellen eine Epithelmonoschicht an dem Gerüst bilden.
  4. Verfahren nach Anspruch 3, wobei das dezellularisierte biologische Matrixgerüst aus einem mukosalen oder submukosalen Gewebe gewonnen wird.
  5. Verfahren nach Anspruch 3, wobei das dezellularisierte biologische Matrixgerüst aus einem Säugetierverdauungskanal gewonnen wird.
  6. Bioartifizielle proximale Tubulusvorrichtung nach Anspruch 1 oder 2 oder Verfahren nach Anspruch 5, wobei das dezellularisierte biologische Matrixgerüst, das aus einem Säugetierverdauungskanal gewonnen wurde, aus dem Magen, Zwölffingerdarm, Leerdarm, Dünndarm oder Dickdarm des Säugetiers gewonnen wird.
  7. Verfahren nach Anspruch 3, wobei die eine oder die mehreren Präkursorzellen aus der Gruppe bestehend aus primären Nierentubulusepithelzellen, induzierbaren pluripotenten Stammzellen, Nierenprogenitorzellen, in Nierenzellen oder Nierenprogenitorzellen differenzierten Progenitorzellen, aus der Niere isolierten Stammzellen oder aus der Niere isolierten Progenitorzellen und Gemischen davon ausgewählt sind.
  8. Bioartifizielle proximale Tubulusvorrichtung nach den Ansprüchen 1, 2 oder 6 oder Verfahren nach Anspruch 3-7, wobei die aus der Niere isolierten Progenitorzellen aus der menschlichen Niere gewonnene Zellen sind.
  9. Bioartifizielle proximale Tubulusvorrichtung nach Anspruch 8 oder Verfahren nach Anspruch 8, wobei die aus der menschlichen Niere gewonnenen Zellen zur Selbsterneuerung und Expansion in der Kultur in der Lage sind und bei der Expression von mindestens einem von Oct-4, Rex-1, Pax-2, Cadherin-11, FoxD1, WT1, Eyal, HNF3B, CXC-R4, Sox-17, EpoR, BMP2, BMP7 oder GDF5 positiv sind; und bei der Expression von mindestens einem von Sox2, FGF4, hTert, Wnt-4, SIX2, E-Cadherin oder GATA-4 negativ sind.
  10. Bioartifizielle proximale Tubulusvorrichtung nach Anspruch 8 oder 9 oder Verfahren nach Anspruch 8 oder 9, wobei die aus der menschlichen Niere gewonnenen Zellen für mindestens einen der Zelloberflächenmarker HLA-I, CD24, CD29, CD44, CD49c, CD73, CD90, CD166 oder SSEA-4 positiv sind; und für mindestens einen der Zelloberflächenmarker HLA II, CD31, CD34, CD45, CD56, CD80, CD86, CD104, CD105, CD117, CD133, CD138 und CD141 negativ.
  11. Bioartifizielle proximale Tubulusvorrichtung nach einem der Ansprüche 8 bis 10 oder Verfahren nach einem der Ansprüche 8 bis 10, wobei die aus der menschlichen Niere gewonnenen Zellen mindestens einen der trophischen Faktoren FGF2, HGF, TGFα, TIMP-1, TIMP-2, MMP-2 oder VEGF sekretieren; und mindestens einen der trophischen Faktoren PDGF-bb oder IL12p70 nicht sekretieren.
  12. Bioartifizielle proximale Tubulusvorrichtung nach Anspruch 9 oder Verfahren nach Anspruch 9, wobei die aus der menschlichen Niere gewonnenen Zellen zur Selbsterneuerung und Expansion in der Kultur in der Lage sind und ferner eine der folgenden Eigenschaften aufweisen:
    a) bei der Expression von einem oder mehreren von Oct-4 und Rex-1 positiv und bei der Expression von einem oder mehreren von Sox2, FGF4, hTert und Wnt-4 negativ; oder
    b) bei der Expression von mindestens einem oder mehreren von Eyal, WT1, FoxD1, BMP7, BMP2, GDF5, EpoR oder Rex-1 positiv und bei der Expression von mindestens einem oder mehreren von Sox2, FGF4, hTert oder Wnt-4 negativ.
  13. Verfahren nach den Ansprüchen 3 und 7, wobei das Verfahren das Funktionieren der natürlichen regulativen Mechanismen von Kontaktinhibition und Bildung einer intakten Monoschicht ohne Verwendung von Kontaktinhibitoren fördert.
EP12726536.1A 2011-05-27 2012-05-25 Bioartifizielle proximale tubulussysteme und anwendungsverfahren Active EP2714894B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL12726536T PL2714894T3 (pl) 2011-05-27 2012-05-25 Systemy biosztucznych kanalików proksymalnych oraz sposoby ich stosowania

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490890P 2011-05-27 2011-05-27
PCT/US2012/039732 WO2012166668A1 (en) 2011-05-27 2012-05-25 Bioartificial proximal tubule systems and methods of use

Publications (2)

Publication Number Publication Date
EP2714894A1 EP2714894A1 (de) 2014-04-09
EP2714894B1 true EP2714894B1 (de) 2019-10-30

Family

ID=46229935

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12726536.1A Active EP2714894B1 (de) 2011-05-27 2012-05-25 Bioartifizielle proximale tubulussysteme und anwendungsverfahren

Country Status (15)

Country Link
US (1) US20120301958A1 (de)
EP (1) EP2714894B1 (de)
JP (2) JP6158175B2 (de)
KR (1) KR102034496B1 (de)
CN (2) CN110511901A (de)
AU (1) AU2012262382B2 (de)
BR (1) BR112013030567B1 (de)
CA (1) CA2837462C (de)
ES (1) ES2764850T3 (de)
MX (1) MX2013013877A (de)
PL (1) PL2714894T3 (de)
RU (1) RU2620947C2 (de)
SG (1) SG195125A1 (de)
WO (1) WO2012166668A1 (de)
ZA (1) ZA201309678B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240144472A (ko) * 2013-05-08 2024-10-02 인리젠 단리된 신장 세포를 포함하는 오가노이드 및 이의 용도
WO2015152025A1 (ja) * 2014-03-31 2015-10-08 テルモ株式会社 シート状細胞培養物の品質評価方法
JP6755085B2 (ja) * 2015-11-10 2020-09-16 日機装株式会社 細胞支持複合体および細胞支持複合体の製造方法
WO2018186185A1 (ja) 2017-04-06 2018-10-11 日機装株式会社 細胞の培養方法、細胞支持複合体の製造方法、培養細胞及び細胞支持複合体
CN108588006A (zh) * 2018-05-10 2018-09-28 华东理工大学 一种用于肝细胞三维培养的生物支架及其制备方法和应用
JP7141688B2 (ja) * 2018-05-15 2022-09-26 学校法人北里研究所 近位尿細管上皮細胞株及びその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
CA2466487C (en) * 2001-11-16 2011-04-05 Children's Medical Center Corporation Augmentation of organ function
WO2003053217A2 (en) * 2001-12-07 2003-07-03 Kropp Bradley P Tissue graft compositions and methods for producing same
IL164048A0 (en) * 2002-03-15 2005-12-18 Univ North Carolina Primitive and proximal hepatic stemcells
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium
KR20140040293A (ko) * 2005-08-26 2014-04-02 리전츠 오브 더 유니버스티 오브 미네소타 기관 및 조직의 세포제거 및 재세포화
PT2078073E (pt) * 2006-10-12 2013-11-11 Ethicon Inc Células derivadas do rim e métodos de utilização na reparação e regeneração de tecidos
ATE548059T1 (de) 2006-10-17 2012-03-15 Univ Tokai Educational System Bioartifizieller nierentubulus
WO2008151254A1 (en) * 2007-06-04 2008-12-11 The Regents Of The University Of California Methods of tissue generation and tissue engineered compositions
WO2009072990A1 (en) * 2007-12-06 2009-06-11 Agency For Science, Technology And Research Method for extracellular matrix mediated differentiation and proliferation of stem cells
EP2177603A1 (de) * 2008-09-25 2010-04-21 Gambro Lundia AB Vorrichtung für Nierenzellexpansion
DE102008056037B4 (de) 2008-11-05 2012-10-31 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Mikrofluidischer Bioreaktor
WO2010057015A1 (en) * 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
EP2370564A4 (de) 2008-12-02 2013-11-06 Agency Science Tech & Res Verfahren zur herstellung von nierentubuli
EP2413946A2 (de) * 2009-03-31 2012-02-08 Regents of the University of Minnesota Dezellularisierung und rezellularisierung von organen und geweben

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
CA2837462C (en) 2021-06-01
JP2014515270A (ja) 2014-06-30
CA2837462A1 (en) 2012-12-06
RU2013158327A (ru) 2015-07-10
KR102034496B1 (ko) 2019-10-22
AU2012262382A1 (en) 2013-12-12
CN110511901A (zh) 2019-11-29
SG195125A1 (en) 2013-12-30
US20120301958A1 (en) 2012-11-29
BR112013030567A2 (pt) 2017-07-04
WO2012166668A1 (en) 2012-12-06
PL2714894T3 (pl) 2020-04-30
KR20140042824A (ko) 2014-04-07
JP6523358B2 (ja) 2019-05-29
JP2017099417A (ja) 2017-06-08
MX2013013877A (es) 2014-05-28
RU2620947C2 (ru) 2017-05-30
ZA201309678B (en) 2015-08-26
CN103842497A (zh) 2014-06-04
BR112013030567B1 (pt) 2021-02-17
JP6158175B2 (ja) 2017-07-05
EP2714894A1 (de) 2014-04-09
AU2012262382B2 (en) 2016-10-13
AU2012262382A8 (en) 2014-01-16
ES2764850T3 (es) 2020-06-04

Similar Documents

Publication Publication Date Title
JP6523358B2 (ja) バイオ人工近位尿細管システム及びその使用方法
Machida et al. Primary rat muscle progenitor cells have decreased proliferation and myotube formation during passages
US8778607B2 (en) Method of in vitro toxicity testing using isolated liver stem cells
EP3223831B1 (de) Verfahren zur erzeugung von podozyten aus pluripotenten stammzellen und dadurch hergestellte zellen
Kamiya et al. Enrichment and clonal culture of progenitor cells during mouse postnatal liver development in mice
US20050260748A1 (en) Adult stem cells and uses thereof
Yoshioka et al. A modified pre-plating method for high-yield and high-purity muscle stem cell isolation from human/mouse skeletal muscle tissues
US9605244B2 (en) Method of differentiating mammalian progenitor cells into insulin producing pancreatic islet cells
TWI448554B (zh) 肝星形細胞前驅體及其分離方法
CN111432824A (zh) 铺板肝细胞及其制备和用途
Yoshizato Growth potential of adult hepatocytes in mammals: Highly replicative small hepatocytes with liver progenitor‐like traits
WO2024206169A1 (en) Applications of hepatocyte co-culture system
WO2019131938A1 (ja) 機能的肝前駆細胞もしくは肝細胞または機能的小腸上皮前駆細胞もしくは小腸上皮細胞を調製する方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131231

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160719

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190208

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAZANECKI, CHRISTIAN

Inventor name: HOPPENSACK, ANKE

Inventor name: SCHANZ, JOHANNA

Inventor name: COLTER, DAVID C.

Inventor name: HANSMANN, JAN

Inventor name: WALLES, HEIKE

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190617

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEPUY SYNTHES PRODUCTS, INC.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1196152

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012065245

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200302

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200130

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200131

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200229

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2764850

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012065245

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1196152

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210427

Year of fee payment: 10

Ref country code: IT

Payment date: 20210412

Year of fee payment: 10

Ref country code: FR

Payment date: 20210412

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20210415

Year of fee payment: 10

Ref country code: ES

Payment date: 20210609

Year of fee payment: 10

Ref country code: GB

Payment date: 20210428

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012065245

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220525

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230728

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220526